Supernus Pharmaceuticals | SUPN - Interest Income


Supernus Pharmaceuticals reported $2.38M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Abbott USD 106M 28M Mar/2026
Aurora Cannabis CAD 1.04M 808K Mar/2026
Canopy Growth CAD 3.86M 1.89M Mar/2026
Cara Therapeutics USD 347K 74K Mar/2025
Corcept Therapeutics USD 4.89M 537K Mar/2026
Eisai JPY 3.11B 783M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Pacira USD 1.93M 365K Mar/2026
Pfizer USD -0.04 115M Jun/2026
Supernus Pharmaceuticals USD 2.38M 359K Mar/2026
United Therapeutics USD 31.5M 10.3M Jun/2026
Xeris Pharmaceuticals USD 1.2M 44K Mar/2026